NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit
U.S., Canada Begin ExCel Trial To Evaluate Aromasin For Breast Cancer Prevention
Avastin Improves PFS In Advanced Breast Cancer
Preoperative Drug Combo Benefits HER-2 Breast Cancer
Combination Radiation/Vaccine May Benefit Some Patients
“Inoperable” Prostate Cancer May Be Operable, Curable
Benefit Seen In Novel Drug That Treats Gleevec Resistance
NCI’s Rosenberg Confirms 2002 Immunotherapy Results
NCI-Approved Clinical Trials
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”









